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We thank McGirr and colleagues for their
interest in our manuscript entitled ‘‘Clinical and
Economic Impact of a Potential Switch from
13-Valent to 10-Valent Pneumococcal Conju-
gate Infant Vaccination in Canada.’’ They raise
several questions related to our novel approach
to pneumococcal disease modeling, and we
appreciate the opportunity to provide further
clarification.
1. Differences in serotype distribution as well
as immunization rates vary between pro-
vinces, and use of regional data may not be
representative of the whole of Canada.
In their letter, McGirr et al. question the choice
of the data set used for our model input and its
representativeness of national trends. They fur-
ther cite several other data sets with broader
national reach as more appropriate for our
analysis. In Canada, decisions about, and
administration of, immunization programs are
made on a provincial level, and programs differ
between jurisdictions with respect to the year of
introduction, immunization schedules imple-
mented, and vaccine used, etc. (e.g., some pro-
vinces had a short period of PCV10 use, while
the majority transitioned directly to PCV13).Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.7240973.
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Subsequently, any surveillance program that
collects data on a national basis (such as
IMPACT https://www.cps.ca/en/impact and
National Microbiology Laboratory (NML)
surveillance) represents a mixture of these dif-
ferent provincial immunization programs. In
addition, NML surveillance—only available
starting in 2011—is passive, and the Public
Health Agency of Canada cautions on the
interpretation of these data (PHAC, [14].
Surveillance is based on provincial reporting
into the NML, which is done on a voluntary
basis, and provinces may submit only a subset
of laboratory isolates for testing. The CNDSS
data set does not include serotyping informa-
tion, and the eIMD data set is a pilot project
launched in 2011 in the small province of New
Brunswick; therefore, these were not considered
appropriate for our modeling.
Becauseourmodeling approach isbased onthe
historical behavior of each serotype, it was crucial
to have access to a serotype-specific data set by age
and by year starting from 2001. Data from the
Toronto Invasive Bacterial Diseases Network
(TIBDN), an active, population-based, long-s-
tanding surveillance initiative, satisfied these cri-
teria. While we acknowledge the limitations of
extrapolating a single province to the rest of
Canada, we believe this selection of data set was a
conservative one, as use of data from Quebec—
where quality surveillance data are also avail-
able—produced more favorable ICERs towards
PCV13 and was previously presented at the 2016
Canadian Immunization Conference [19].
2. The approach taken is not recommended by
ISPOR or SMDM guidelines.
McGirr and colleagues claim that the ISPOR-
SMDM task force guidelines call for state-tran-
sition models, discrete event simulations, or
dynamic transmission models as the best-prac-
tice approach [2]. While the approaches were
noted as commonly used methods, it was not
presented as an exhaustive list of accept-
able methods. As noted in the introduction of
our article, while a dynamic transmission model
could have been developed to answer the
question, data limitations, complexity of the
model, and lack of information to support the
numerous parameters in such a model would
have limited its relevance. As such, we devel-
oped a straightforward, transparent model dri-
ven by observed, real-world evidence rather
than clinical efficacy. This is a critical differen-
tiator of our approach from various other
pneumococcal disease models that rather use
clinical efficacy assumptions or methods that
do not or differently capture indirect effects
[17].
3. Concerns about the trend lines and
methodology.
McGirr and colleagues note concerns about the
methodology, particularly around the R2 values.
Low R2 values were primarily observed in ser-
otypes responsible for few or no cases of disease
(e.g., serotypes 1 and 6A) or in populations in
which incidence was low (ages 18–34, 35–49
years). Therefore, in these cases the impact is
expected to be modest as the model predicted
few cases to occur for either vaccine. Over 70%
of cases were observed in the\5 and[ 65 year
populations and driven primarily by serotype
19A where model fits were strong (R2 values [
0.79). We think that R2 provided an unbiased
approach to the selection of the mathematical
function to represent the vaccine, serotype, and
age group. While we did not include the trend
lines in the probabilistic sensitivity analysis—as
we have no mathematical estimates of the
uncertainty of the data—we performed sensi-
tivity analyses using various trend lines from
countries that have implemented either PCV13
or PCV10 to capture uncertainty in vaccine
behavior under different epidemiologic set-
tings. These analyses would likely predict com-
parable ranges to traditional sensitivity analysis
around the base case.
4. Potential cross-reactivity of the 10-valent
vaccine with serotype 19A.
McGirr and colleagues correctly allude to a pair
of case-control studies in Finland and Brazil that
suggested cross-protection of the 10-valent
vaccine with serotype 19A [9, 12]; however,
their statement that ‘‘the approach used by
Wilson et al. did not account for this cross-re-
activity against serotype 19A’’ is not correct. The
strength of our novel methodology is that
explicit assumptions on cross-reactivity, vaccine
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efficacy, and related parameters are not neces-
sary; our model incorporates longitudinal vac-
cine performance under real-world settings.
Therefore, the model utilizes data that inher-
ently account for any 19A cross-protection (or
any other serotypes for that matter). This 19A
evidence has been summarized in depth in a
recent systematic review [11]. Furthermore,
surveillance data after a switch from PCV13 to
PCV10 in Belgium became available after the
publication of our manuscript [8]. By the end of
2017, only 8 to 18 months following the switch
to PCV10 in the two Belgian regional immu-
nization programs (Flanders in July 2015 and
Wallonia in May 2016), a nationwide tenfold
increase in serotype 19A IPD cases in chil-
dren B 2 years of age was observed with this
trend continuing into 2018 [8]. However, fur-
ther analyses of these data are required before
definite conclusions can be drawn.
5. Impact on mucosal disease.
McGrirr and colleagues challenge the approach
of extrapolating serotype-specific IPD incidence
to acute otitis media (AOM) and pneumonia.
While we agree that predictions of AOM and
pneumonia are complicated by the presence of
multiple causative pathogens, this method is
well accepted as changes in IPD incidence
would be driven by changes in circulating car-
riage of disease-causing serotypes [15–17].
McGirr and colleagues also suggest that the
model omits any potential benefit of PCV10 in
reducing cases of AOM caused by non-typeable
Haemophilus influenzae (NTHi) and that this
exclusion biases the results against PCV10. Pre-
vious cost-effectiveness studies favoring PCV10
are strongly driven by this benefit
[3, 7, 10, 18, 20]. However, we believe that
additional evidence for both vaccines is neces-
sary to quantify the impact on AOM beyond S.
pneumoniae (such as NTHi or any other patho-
gen causing AOM) in cost-effectiveness analyses
[1, 5, 6, 13, 17]. Therefore, we took a conserva-
tive approach by excluding NTHi impact from
our analyses. This was outlined in our manu-
script and has been summarized in depth else-
where [13, 17].
6. Results are inconsistent with the health
economic assessment conducted by the
Comite´ sur l’immunisation du Que´bec
(CIQ).
A recent analysis by CIQ including children\5
years and only IPD found a 2 ? 1 PCV10
schedule would be cost-effective compared with
a 2 ? 1 PCV13 schedule [4]. We note that our
analysis differs in that it includes: the impact of
indirect effects (impact in the popula-
tion C 5 years), impact of PCVs on non-invasive
disease (pneumonia and otitis media), and
impact of disease on QALYs lost; most impor-
tantly, our analysis accounts for the costs
required to treat additional cases of disease
resulting from a switch to a 2 ? 1 PCV10
schedule.
In closing, we thank McGirr and colleagues
for their thorough assessment of our article. We
acknowledge that our results are prone to
specific assumptions, and alternate assumptions
could lead to alternate results, although our
results were robust to sensitivity analyses per-
formed. We hope that our answers clarified our
analysis.
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